<DOC>
	<DOC>NCT00860288</DOC>
	<brief_summary>This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as add-on therapy to metformin</brief_summary>
	<brief_title>Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients 1878 years old inclusive at Visit 1 T2DM patients treated with metformin for at least 3 months and a stable dose of at least 1500 mg daily for a minimum of 4 weeks prior to Visit 1 Patient agreement to maintain same dose of metformin throughout study HbA1c of ≥ 7.0 and ≤ 9.5 % at Visit 1 Body Mass Index (BMI) in the range of 2245 kg/m2 at visit 1 Pregnant or nursing (lactating) women FPG ≥ 270 mg/dL ( ≥ 15.0 mmol/L)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>vildagliptin</keyword>
</DOC>